drugset
drugset / Trial / NCT03674060

Study to Compare Pharmacokinetic Property of SYO-1644 Tab. and Nexavar Tab. in Healthy Male Volunteers

NCT03674060 ↗

Phase 1 Completed 32 enrolled Samyang Biopharmaceuticals Corporation Seoul National University Hospital · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics characteristics ,tolerability, and safety after orally administrating SYO-1644 to healthy male volunteers in randomized, active-controlled, open-label clinical study.

Timeline

Start
2018-10-28
Primary completion
2019-02-08
Completion
2019-07-23

Drugs

EvaluationDrugModalityDoseRoute
Subject SYO-1644 Unknown 100 mg Oral
Subject SYO-1644 Unknown 150 mg Oral
Subject SYO-1644 Unknown 200 mg Oral
Comparator Sorafenib Small molecule 200 mg Oral

Indications

No indication recorded.